Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Dhara Shah

Physician Assistant, Medical Smithfield, RI Physician Assistant

NPI 1194475442 CMS profile 11310057

41 Sanderson Rd Ste 206B, Smithfield, RI 02917

Open in the dashboard

General payments

$6,042

274 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dhara Shah of Smithfield, RI is reported in the CMS Open Payments database as having received $6,042 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,668 83
2024 General $1,355 63
2023 General $1,943 88
2022 General $1,076 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhara Shah
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Dhara Shah were reported at $1,668. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Dhara Shah Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $1,076 $185 $55–$649 $149
2023 $1,943 $199 $58–$717 $160
2024 $1,355 $206 $62–$740 $164
2025 $1,668 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $1,011 49 payments
  2. AbbVie, Inc. $710 34 payments
  3. AstraZeneca Pharmaceuticals LP $676 26 payments
  4. Pfizer Inc. $619 31 payments
  5. GlaxoSmithKline, LLC. $425 19 payments
  6. Lilly USA, LLC $362 19 payments
  7. Collegium Pharmaceutical, Inc. $246 19 payments
  8. Novartis Pharmaceuticals Corporation $244 7 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $236 10 payments
  10. Exact Sciences Corporation $232 10 payments
  11. Other $1,280 50 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,042 274 payments
Products named General payments · program years 2022–2025
  1. Ozempic $836 41 payments
  2. RYBELSUS $836 41 payments
  3. UBRELVY $427 23 payments
  4. NURTEC ODT $405 20 payments
  5. ZAVZPRET $261 12 payments
  6. XTAMPZA $246 19 payments
  7. FARXIGA $246 11 payments
  8. BREZTRI $237 7 payments
  9. SPIRIVA RESPIMAT $227 10 payments
  10. VRAYLAR $225 9 payments
  11. Other $4,090 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

6,747

Median for Physician Assistant: 241

Drug cost

$462,423

Median for Physician Assistant: $4,110

Branded share of claims

17.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 109 $100,644
Ozempic Semaglutide Brand 76 $87,175
Eliquis Apixaban Brand 79 $67,486
Rybelsus Semaglutide Brand 24 $34,061
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 61 $33,771
Januvia Sitagliptin Phosphate Brand 27 $18,517
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $15,549
Xarelto Rivaroxaban Brand 12 $9,583
Atorvastatin Calcium Generic 520 $5,347
Omeprazole Generic 292 $4,309

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$34,223

Medicare's payments for the services billed

Medicare patients

175

Average age 75

Services billed

558

132 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 31%
Chronic kidney disease 30%
Depression 25%
Atrial fibrillation 21%
COPD 21%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $95
  • Boehringer Ingelheim Pharmaceuticals, Inc. $65
$160 109 —
RYBELSUS
  • Novo Nordisk Inc $110
$110 24 —
Ozempic
  • Novo Nordisk Inc $110
$110 76 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $103
$103 — —
UBRELVY
  • AbbVie, Inc. $93
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record